Toll Free: 1-888-928-9744

Myocardial Infarction - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 358 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myocardial Infarction - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Myocardial Infarction - Pipeline Review, H1 2016', provides an overview of the Myocardial Infarction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Myocardial Infarction Overview 11 Therapeutics Development 12 Pipeline Products for Myocardial Infarction - Overview 12 Pipeline Products for Myocardial Infarction - Comparative Analysis 13 Myocardial Infarction - Therapeutics under Development by Companies 14 Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 19 Myocardial Infarction - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Myocardial Infarction - Products under Development by Companies 25 Myocardial Infarction - Products under Investigation by Universities/Institutes 30 Myocardial Infarction - Companies Involved in Therapeutics Development 32 Amarantus Bioscience Holdings, Inc. 32 Angion Biomedica Corp. 33 Asterias Biotherapeutics, Inc. 34 AstraZeneca Plc 35 Athersys, Inc. 36 Bayer AG 37 Bharat Biotech International Limited 38 BioCardia, Inc. 39 Biscayne Pharmaceuticals, Inc. 40 Capricor Therapeutics, Inc. 41 CellProthera 42 Celyad SA 43 Compugen Ltd. 44 CSL Limited 45 Cynata Therapeutics Limited 46 FibroGen, Inc. 47 Hemostemix Ltd 48 Human Stem Cells Institute 49 HUYA Bioscience International, LLC 50 Immune Pharmaceuticals Inc. 51 Juventas Therapeutics, Inc. 52 Laboratoires Pierre Fabre SA 53 Lee's Pharmaceutical Holdings Limited 54 LegoChem Biosciences, Inc 55 LG Life Science LTD. 56 Medestea Research & Production S.p.A. 57 Mesoblast Limited 58 miRagen Therapeutics, Inc. 59 Moderna Therapeutics, Inc. 60 MorphoSys AG 61 NeuroVive Pharmaceutical AB 62 New World Laboratories, Inc. 63 Novartis AG 64 Omeros Corporation 65 Otsuka Holdings Co., Ltd. 66 Pfizer Inc. 67 Polyphor Ltd. 68 Primary Peptides, Inc. 69 Quantum Genomics SA 70 Quark Pharmaceuticals, Inc. 71 Recardio GmbH 72 Serodus ASA 73 Silver Creek Pharmaceuticals, Inc. 74 Stealth BioTherapeutics Inc. 75 Stemedica Cell Technologies, Inc. 76 Stempeutics Research Private Limited 77 TaiGen Biotechnology Co., Ltd. 78 Targazyme, Inc. 79 The International Biotechnology Center (IBC) Generium 80 TiGenix NV 81 Vicore Pharma AB 82 XBiotech USA, Inc. 83 Yuyu Pharma, Inc. 84 Zydus Cadila Healthcare Limited 85 Myocardial Infarction - Therapeutics Assessment 86 Assessment by Monotherapy Products 86 Assessment by Combination Products 87 Assessment by Target 88 Assessment by Mechanism of Action 92 Assessment by Route of Administration 95 Assessment by Molecule Type 97 Drug Profiles 99 (sacubitril + valsartan) - Drug Profile 99 AB-002 - Drug Profile 102 ACP-01 - Drug Profile 104 Alda-1 - Drug Profile 106 alteplase biosimilar - Drug Profile 107 AMRS-001 - Drug Profile 108 ANG-4011 - Drug Profile 111 Antisense RNAi Oligonucleotide to Inhibit miR-92 for Myocardial Infarction - Drug Profile 112 AP-102 - Drug Profile 113 APO-1 - Drug Profile 114 balixafortide - Drug Profile 115 Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction and Inflammation - Drug Profile 116 BIS-5409 - Drug Profile 117 bococizumab - Drug Profile 118 burixafor - Drug Profile 119 C-21 - Drug Profile 121 C3BSGQR-3 - Drug Profile 123 C3BSGQR-4 - Drug Profile 124 CAP-1001 - Drug Profile 125 CAP-1002 - Drug Profile 126 cenderitide - Drug Profile 128 CGEN-856S - Drug Profile 130 CIGB-500 - Drug Profile 132 CM-1 - Drug Profile 133 Cryocell - Drug Profile 135 CSL-112 - Drug Profile 136 CTX-101 - Drug Profile 138 cyclosporine - Drug Profile 140 Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile 141 Drugs to Inhibit SIRT2 for Ischemic Stroke and Myocardial Infarction - Drug Profile 142 dutogliptin tartrate - Drug Profile 143 elamipretide - Drug Profile 145 Ephrin A-1 for Myocardial Infarction - Drug Profile 147 F-573 - Drug Profile 148 FG-6874 - Drug Profile 149 Gemacell - Drug Profile 150 Gene Therapy for Acute Myocardial Infarction - Drug Profile 151 HBI-3802 - Drug Profile 152 HYPER-IL-6 - Drug Profile 153 ICG-001 - Drug Profile 154 IS-20 - Drug Profile 155 JI-38 - Drug Profile 156 JVS-100 - Drug Profile 157 JVS-200 - Drug Profile 159 KR-33028 - Drug Profile 160 LC-280126 - Drug Profile 161 LWnt-3a - Drug Profile 163 Lysimab - Drug Profile 164 MGN-1374 - Drug Profile 165 MGN-6114 - Drug Profile 166 MIF-2 - Drug Profile 167 MIF-20 - Drug Profile 168 Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 169 Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile 170 MPC-150IM - Drug Profile 171 MPC-25IC - Drug Profile 173 Neu-2000 - Drug Profile 174 NP-202 - Drug Profile 176 NVP-019 - Drug Profile 178 NVX-308 - Drug Profile 179 NWL-53 - Drug Profile 180 Oligonucleotide for Oncology and Cardiovascular - Drug Profile 181 Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile 182 OMS-721 - Drug Profile 184 OPC-28326 - Drug Profile 186 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 188 Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 190 PF-05285401 - Drug Profile 191 Polyglactin 370 for Acute Myocardial Infarction - Drug Profile 196 PP-001 - Drug Profile 197 Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 198 ProtheraCytes - Drug Profile 199 QGC-101 - Drug Profile 201 QPCP-1 - Drug Profile 202 RBB-001 - Drug Profile 203 Recombinant Protein for Cardiovascular Diseases - Drug Profile 204 Recombinant Protein for Myocardial Infarction - Drug Profile 205 Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile 206 Recombinant Prourokinase - Drug Profile 207 remestemcel-L - Drug Profile 208 rivaroxaban - Drug Profile 212 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile 218 salicylamine - Drug Profile 219 SER-130 - Drug Profile 220 Small Molecule for Myocardial Infarction - Drug Profile 221 Small Molecule for Reperfusion Injury and Heart Attack - Drug Profile 222 Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 223 Small Molecules for Myocardial Infarction and Inflammation - Drug Profile 224 Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile 225 Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile 226 Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 227 Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 228 Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 229 Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile 230 Stem Cell Therapy for Acute Myocardial Infarction - Drug Profile 231 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 232 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 233 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 236 Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 238 Stempeucel - Drug Profile 239 Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 242 TF-0023 - Drug Profile 243 THR-100 - Drug Profile 244 ticagrelor - Drug Profile 246 TZ-101 - Drug Profile 250 VN-100 - Drug Profile 252 ZK-001 - Drug Profile 253 Myocardial Infarction - Recent Pipeline Updates 255 Myocardial Infarction - Dormant Projects 330 Myocardial Infarction - Discontinued Products 339 Myocardial Infarction - Product Development Milestones 340 Featured News & Press Releases 340 Appendix 349 Methodology 349 Coverage 349 Secondary Research 349 Primary Research 349 Expert Panel Validation 349 Contact Us 349 Disclaimer 350
List of Tables
Number of Products under Development for Myocardial Infarction, H1 2016 20 Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2016 21 Number of Products under Development by Companies, H1 2016 22 Number of Products under Development by Companies, H1 2016 (Contd..1) 23 Number of Products under Development by Companies, H1 2016 (Contd..2) 24 Number of Products under Development by Companies, H1 2016 (Contd..3) 25 Number of Products under Development by Companies, H1 2016 (Contd..4) 26 Number of Products under Investigation by Universities/Institutes, H1 2016 28 Comparative Analysis by Late Stage Development, H1 2016 29 Comparative Analysis by Clinical Stage Development, H1 2016 30 Comparative Analysis by Early Stage Development, H1 2016 31 Comparative Analysis by Unknown Stage Development, H1 2016 32 Products under Development by Companies, H1 2016 33 Products under Development by Companies, H1 2016 (Contd..1) 34 Products under Development by Companies, H1 2016 (Contd..2) 35 Products under Development by Companies, H1 2016 (Contd..3) 36 Products under Development by Companies, H1 2016 (Contd..4) 37 Products under Investigation by Universities/Institutes, H1 2016 38 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 39 Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 40 Myocardial Infarction - Pipeline by Angion Biomedica Corp., H1 2016 41 Myocardial Infarction - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 42 Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2016 43 Myocardial Infarction - Pipeline by Athersys, Inc., H1 2016 44 Myocardial Infarction - Pipeline by Bayer AG, H1 2016 45 Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H1 2016 46 Myocardial Infarction - Pipeline by BioCardia, Inc., H1 2016 47 Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 48 Myocardial Infarction - Pipeline by Capricor Therapeutics, Inc., H1 2016 49 Myocardial Infarction - Pipeline by CellProthera, H1 2016 50 Myocardial Infarction - Pipeline by Celyad SA, H1 2016 51 Myocardial Infarction - Pipeline by Compugen Ltd., H1 2016 52 Myocardial Infarction - Pipeline by CSL Limited, H1 2016 53 Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H1 2016 54 Myocardial Infarction - Pipeline by FibroGen, Inc., H1 2016 55 Myocardial Infarction - Pipeline by Hemostemix Ltd, H1 2016 56 Myocardial Infarction - Pipeline by Human Stem Cells Institute, H1 2016 57 Myocardial Infarction - Pipeline by HUYA Bioscience International, LLC, H1 2016 58 Myocardial Infarction - Pipeline by Immune Pharmaceuticals Inc., H1 2016 59 Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H1 2016 60 Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 61 Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 62 Myocardial Infarction - Pipeline by LegoChem Biosciences, Inc, H1 2016 63 Myocardial Infarction - Pipeline by LG Life Science LTD., H1 2016 64 Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H1 2016 65 Myocardial Infarction - Pipeline by Mesoblast Limited, H1 2016 66 Myocardial Infarction - Pipeline by miRagen Therapeutics, Inc., H1 2016 67 Myocardial Infarction - Pipeline by Moderna Therapeutics, Inc., H1 2016 68 Myocardial Infarction - Pipeline by MorphoSys AG, H1 2016 69 Myocardial Infarction - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 70 Myocardial Infarction - Pipeline by New World Laboratories, Inc., H1 2016 71 Myocardial Infarction - Pipeline by Novartis AG, H1 2016 72 Myocardial Infarction - Pipeline by Omeros Corporation, H1 2016 73 Myocardial Infarction - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 74 Myocardial Infarction - Pipeline by Pfizer Inc., H1 2016 75 Myocardial Infarction - Pipeline by Polyphor Ltd., H1 2016 76 Myocardial Infarction - Pipeline by Primary Peptides, Inc., H1 2016 77 Myocardial Infarction - Pipeline by Quantum Genomics SA, H1 2016 78 Myocardial Infarction - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 79 Myocardial Infarction - Pipeline by Recardio GmbH, H1 2016 80 Myocardial Infarction - Pipeline by Serodus ASA, H1 2016 81 Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals, Inc., H1 2016 82 Myocardial Infarction - Pipeline by Stealth BioTherapeutics Inc., H1 2016 83 Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 84 Myocardial Infarction - Pipeline by Stempeutics Research Private Limited, H1 2016 85 Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 86 Myocardial Infarction - Pipeline by Targazyme, Inc., H1 2016 87 Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 88 Myocardial Infarction - Pipeline by TiGenix NV, H1 2016 89 Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2016 90 Myocardial Infarction - Pipeline by XBiotech USA, Inc., H1 2016 91 Myocardial Infarction - Pipeline by Yuyu Pharma, Inc., H1 2016 92 Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 93 Assessment by Monotherapy Products, H1 2016 94 Assessment by Combination Products, H1 2016 95 Number of Products by Stage and Target, H1 2016 97 Number of Products by Stage and Mechanism of Action, H1 2016 101 Number of Products by Stage and Route of Administration, H1 2016 104 Number of Products by Stage and Molecule Type, H1 2016 106 Myocardial Infarction Therapeutics - Recent Pipeline Updates, H1 2016 263 Myocardial Infarction - Dormant Projects, H1 2016 338 Myocardial Infarction - Dormant Projects (Contd..1), H1 2016 339 Myocardial Infarction - Dormant Projects (Contd..2), H1 2016 340 Myocardial Infarction - Dormant Projects (Contd..3), H1 2016 341 Myocardial Infarction - Dormant Projects (Contd..4), H1 2016 342 Myocardial Infarction - Dormant Projects (Contd..5), H1 2016 343 Myocardial Infarction - Dormant Projects (Contd..6), H1 2016 344 Myocardial Infarction - Dormant Projects (Contd..7), H1 2016 345 Myocardial Infarction - Dormant Projects (Contd..8), H1 2016 346 Myocardial Infarction - Discontinued Products, H1 2016 347


List of Figures
Number of Products under Development for Myocardial Infarction, H1 2016 20 Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2016 21 Number of Products under Development by Companies, H1 2016 22 Number of Products under Investigation by Universities/Institutes, H1 2016 27 Comparative Analysis by Late Stage Development, H1 2016 29 Comparative Analysis by Clinical Stage Development, H1 2016 30 Comparative Analysis by Early Stage Products, H1 2016 31 Assessment by Monotherapy Products, H1 2016 94 Number of Products by Top 10 Targets, H1 2016 96 Number of Products by Stage and Top 10 Targets, H1 2016 96 Number of Products by Top 10 Mechanism of Actions, H1 2016 100 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 100 Number of Products by Top 10 Routes of Administration, H1 2016 103 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 103 Number of Products by Top 10 Molecule Types, H1 2016 105 Number of Products by Stage and Top 10 Molecule Types, H1 2016 105

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify